Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + linagliptin + metformin (EMS)
- Development stage
- Phase 3
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Madalena Association** is an investigational oral fixed-dose triple antihyperglycemic combination developed by EMS for type 2 diabetes mellitus. It contains **empagliflozin**, a sodium-glucose cotransporter 2 inhibitor that promotes urinary glucose excretion; **linagliptin**, a dipeptidyl peptidase-4 inhibitor that prolongs endogenous incretin activity; and **metformin**, a biguanide that reduces hepatic glucose production and improves insulin sensitivity. In the EMS-sponsored Phase III MADALENA study, the single-tablet combination is compared with separately administered metformin plus empagliflozin and linagliptin. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT04670666/))
- Brand names
- Madalena
- Other names
- MadalenaMadalena Association
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on empagliflozin + linagliptin + metformin (EMS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + linagliptin + metformin (EMS).